Search PubMed⌕ Search

Biomedical subjects

K M Latimer

Publications and source records attributed to K M Latimer.

25 records · Page 2Linked to original sources
PubMed1985

The effect of inhaled hexamethonium bromide and atropine sulphate on airway responsiveness to histamine.

The degree of protection against inhaled histamine achieved by inhalation of the ganglion blocker hexamethonium bromide plus placebo, hexamethonium plus atropine sulphate, and placebo plus placebo was examined in six atopic subjects, four of whom had current asthma. Hexamethonium was administered until there was systemic evidence of ganglionic blockade with a postural drop in blood pressure of 31 +/- 7.5 mm Hg (mean +/- SD) (p = 0.01) and an increase in heart rate of 30 +/- 3.1 bpm (mean +/- SD) (p = 0.01). Atropine was inhaled in a dose (18 mg nebulized during tidal breathing) known to produce systemic inhibition of cardiac and salivary cholinergic (muscarinic) receptors. The airway effects were measured by FEV1. Hexamethonium caused bronchoconstriction in all four subjects with asthma, which was reversed by atropine. The mean provocation concentration of histamine to provoke a 20% fall in FEV1 was 2.97 mg/ml after premedication with placebo, it was not different at 2.84 mg/ml after hexamethonium alone, and it increased slightly to 5.31 mg/ml after both hexamethonium and atropine (p = 0.06). The results suggest that the main effect of inhaled histamine is not by reflex bronchoconstriction but rather through stimulation of H1-receptors on airway smooth muscle. Therefore, histamine hyperresponsiveness in asthma is not primarily caused by a defect in the parasympathetic nervous supply to the airway.

Adult↗
PubMed1984

Inhibition by sodium cromoglycate of bronchoconstriction stimulated by respiratory heat loss: comparison of pressurised aerosol and powder.

The protective effect was examined of three doses (2, 10, and 20 mg) of sodium cromoglycate inhaled from a pressurised metered dose inhaler on the response to isocapnic hyperventilation of cold dry air in 10 asthmatic subjects. This was compared with the effect of cromoglycate powder (20 mg) inhaled from a Spincap and with placebo given on two occasions. The medications were inhaled on separate days, in random order and with the use of a double blind double dummy technique, 20 minutes before isocapnic hyperventilation of two fold increasing volumes of air (-15 degrees C, 0% humidity) to produce a 20% fall in the post-treatment FEV1. The response was expressed as the provocative dose of respiratory heat loss required to cause a fall in FEV1 of 15% (PD15, kcal/min). The mean baseline spirometric indices exceeded 85% of predicted normal values on each test day; both placebo treatments reduced the baseline FEV1 by comparison with all active treatments (p less than 0.0001). Comparison of the PD15 on the two placebo days confirmed excellent reproducibility. All doses of cromoglycate shifted the respiratory heat loss dose-response curve to the right of the placebo curve; PD15 after all active treatments exceeded PD15 after placebo (p less than 0.0001). There was no cromoglycate dose-response relationship between the three doses of aerosol (p greater than 0.05), or between any dose of aerosol and powder (p greater than 0.05). It is concluded that cromoglycate aerosol inhaled from a pressurised inhaler in a dose of 2 mg gives the same magnitude of protection against bronchoconstriction stimulated by airway cooling as 20 mg of pressurised aerosol or powder from a Spincap.

Adult↗
PubMed1984

The effect of atropine on allergen-induced increases in bronchial responsiveness to histamine.

We examined the role of cholinergic mechanisms in causing the increase in histamine bronchial responsiveness that follows allergen exposure. Five stable adult atopic asthmatics received inhalation tests with histamine on 2 days after both placebo and a dose of atropine sulphate (18 mg nebulized during tidal breathing), which reduced saliva output. On a third day, an allergen inhalation test was carried out to stimulate a dual asthmatic response. When the FEV1 had returned to within 10% of baseline, the histamine test was repeated after placebo and atropine. Before allergen inhalation, atropine marginally increased the FEV1 (p = 0.12) and reduced bronchial responsiveness to histamine (p = 0.003). When allergen challenge had induced an increase in histamine responsiveness (p = 0.001), atropine again marginally increased FEV1 (p = 0.063) and reduced the responsiveness (p = 0.004) but did not return the responsiveness to the preallergen level (p = 0.023). There was no evidence that the magnitude of the atropine blockade of histamine responsiveness was different before and after allergen (p = 0.92). We conclude that cholinergic mechanisms are not likely to explain the increase in bronchial responsiveness that follows allergen-induced inflammation.

Adult↗
PubMed1983

Bronchoconstriction stimulated by airway cooling. Better protection with combined inhalation of terbutaline sulphate and cromolyn sodium than with either alone.

We compared the effect of inhaled terbutaline sulphate (1,000 micrograms), cromolyn sodium (20 mg), terbutaline plus cromolyn, and placebo on the response to respiratory heat loss (RHL) in 10 asthmatics in whom terbutaline alone did not completely inhibit the response to RHL. The medications were taken double-blind in random order 20 min before voluntary isocapnic hyperventilation of subfreezing air (-14 degrees C, 0% humidity) in twofold-increasing amounts. The response was expressed as the provocative dose of RHL to cause a 10 and 20% fall in forced expiratory volume in one second (FEV1). When compared with placebo, terbutaline produced bronchodilation and inhibition of the response to RHL. The degree of bronchodilation was small (mean delta FEV1, 3.9%) and did not correlate with the degree of protection. Cromolyn produced no bronchodilation and similar inhibition. The effect of terbutaline and cromolyn together was additive. We conclude that when bronchoconstriction stimulated by airway cooling is not prevented by a beta agonist or cromolyn given individually, that it will be more effectively inhibited by the 2 drugs given in combination.

Adult↗
PubMed1982

Salbutamol: comparison of bronchodilating effect of inhaled powder and aerosol in asthmatic subjects.

In the treatment of asthma salbutamol can be administered as an aerosol with a metered-dose inhaler or as a powder with a breath-actuated device (Rotahaler). The two forms of the drug were compared in a double-blind placebo-controlled study involving 10 asthmatic adults who were known to respond to salbutamol. The bronchodilating effect of the aerosol and the powder at doses of 200 micrograms and of the powder at doses of 200 and 400 micrograms was compared, bronchodilation being measured in terms of forced expiratory volume and vital capacity. The response was far greater to salbutamol than to placebo, but there was no significant difference between the two forms of the drug or between the lower and higher doses of powder. No side effects were observed.

Adult↗
PubMed1982

Assessment of beta-adrenoceptor antagonists in asthmatic patients.

1 Bronchial smooth muscle, skeletal muscle and cardiac beta-adrenoceptor antagonism have been compared in twelve asthmatic patients after three beta-adrenoceptor antagonists at two dose levels. The non-selective antagonist propranolol (40 and 160 mg), the non-selective antagonist with partial agonist activity pindolol (5 and 20 mg) and the beta 1-selective antagonist atenolol (50 and 200 mg) were studied on separate occasions. 2 Six placebo days were used in this double-blind crossover study to allow interpretation of individual as well as group results. 3 Bronchial smooth muscle effects were assessed by resting spirometry, histamine inhalation test and spirometric response to inhaled fenoterol. Skeletal muscle effects were assessed by resting tremor and fenoterol induced tremor. 4 Cardiac beta-adrenoceptor antagonism was assessed by measuring the effect on resting heart rate and on maximum heart rate in a standard exercise test. 5 Pindolol tended to cause least change from placebo in resting spirometry, caused significant tremor response, inhibited the fenoterol airway response, and tended to protect against inhaled histamine. 6 Atenolol 60 mg was the only drug to allow a fenoterol airway response similar to placebo. Atenolol increased the inhaled histamine responsiveness. 7 Propranolol 160 mg caused the most reduction in spirometry but also tended to cause the maximum reduction in exercise heart rate. Propranolol caused increased inhaled histamine responsiveness. 8 Initial sensitivity to inhaled histamine did not necessarily predict significant reduction in an asthmatics' spirometry by a beta-adrenoceptor antagonist. The effect of a beta-adrenoceptor antagonist on histamine responsiveness does not correspond to its effect on inhaled beta 2-adrenoceptor agonist responsiveness.

Adrenergic beta-Antagonists↗